Managed Access Program for Momelotinib in Myelofibrosis

N/ANo Longer AvailableNCT05582083

GlaxoSmithKline

Overview

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

Study Type

EXPANDED_ACCESS

Conditions

Myelofibrosis Primary Myelofibrosis

Interventions

MomelotinibDRUG

Momelitinib available as tablets.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent can be obtained from the patient or legally authorised representative as per local regulations * Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia * 18 years or older (at the time consent is obtained) * The patient is willing to abide by the contraception requirements. * No known hypersensitivity to momelotinib, its metabolites, or any of the formulation excipients Exclusion Criteria: * Pregnant or breastfeeding female

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.